BioSpace News Archive

IND Submitted to FDA for Planned Clinical Study at Hackensack University Medical Center to Evaluate RYANODEX for Treatment of COVID-19 Patients

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk based fibers, announces the Company will an online press conference

Smith to Deepen Strategic Leadership and Complement Commercial, Operational and Financial Expertise of the Board

Zimmer Biomet Holdings, Inc. announced its first quarter sales and earnings conference call will be broadcast over the Internet on Monday, May 11, 2020, at 8:30 a.m. Eastern Time.

Provention Bio, Inc. announced the initiation of the rolling submission of the Company’s Biologic License Application to the U.S. Food and Drug Administration for teplizumab, an anti-CD3 monoclonal antibody for the delay or prevention of clinical Type 1 Diabetes in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.

Single ad hoc interim analysis for SIERRA trial to be exercised at the Company’s discretion in Q2 2020, making topline data results available in Q4 2020

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly approved by shareholders by way of a poll. The results of the poll are available on the Investors section of the Company’s website, www.veronapharma.com. About Ver

TraceLink Inc., the leading digital platform company for the life sciences industry, today announced the commitment of a $1 million donation to COVID-19 charitable relief efforts, seeking grant proposals from eligible organizations around the world, effective immediately.

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter financial results on Thursday, April 30, 2020 . The Company will also host a conference call beginning at 8:30 a.m. (EST) .

Kubota Vision Inc., formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the signing of an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 inhibitor compounds discovered by Kubota Vision.